Knight Therapeutics (OTCMKTS:KHTRF – Get Free Report) is anticipated to release its resultson Thursday, March 19th. Analysts expect Knight Therapeutics to post earnings of ($0.0029) per share and revenue of $118.1870 million for the quarter.
Knight Therapeutics Stock Performance
Shares of KHTRF opened at $4.32 on Thursday. Knight Therapeutics has a 12 month low of $3.79 and a 12 month high of $4.72. The firm has a fifty day simple moving average of $4.40 and a 200 day simple moving average of $4.38.
About Knight Therapeutics
Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.
Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.
See Also
- Five stocks we like better than Knight Therapeutics
- What a Former CIA Agent Knows About the Coming Collapse
- I tried out Elon Musk’s new AI tech — it floored me
- “I just bought 10,000 shares of a $5 stock…”
- The Next Commodity Crunch (bigger than oil?)
- Nvidia CEO Issues Bold Tesla Call
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
